Annexon Narrows Loss in Fiscal Q2
Annexon (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing therapies for serious autoimmune and neurodegenerative diseases, released its second quarter 2025 financial results on August 14, 2025. The company’s net loss per share (GAAP) was $0.34, beating analyst expectations of $(0.37) GAAP EPS. This smaller-than-expected GAAP loss came amid higher spending on research and development, with no revenue reported during the period, which aligns with its pre-commercial status. Annexon’s cash, cash equivalents, and short-term investments were $227.0 million as of June 30, 2025, supporting its clinical programs and late-stage development into the fourth quarter of 2026. Overall, the quarter reflected significant progress in the company’s clinical pipeline, but also a continued burn of cash as it invests in late-stage trials and regulatory submissions.
Source: Analyst estimates for the quarter provided by FactSet.
Annexon develops therapeutic antibodies and oral inhibitors targeting the complement pathway, a part of the immune system linked to autoimmune and neurodegenerative conditions. Its business revolves around advancing new therapies for diseases with limited or no current treatment options, focusing on disorders like Guillain-Barré Syndrome (GBS), geographic atrophy (GA) in age-related macular degeneration, and chronic autoimmune diseases.
Source Fool.com
